LPU
MRNA icon

Lansdowne Partners (UK)’s Moderna MRNA Stock Holding History

Lansdowne Partners (UK)’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-35,000
Closed -$1.46M – 23
2024
Q4 		$1.46M Buy
+35,000
New +$1.67M 0.11% 17
2024
Q3 		– Sell
-20,500
Closed -$2.43M – 28
2024
Q2 		$2.43M Sell
20,500
-15,500
-43% -$1.96M 0.19% 15
2024
Q1 		$3.84M Sell
36,000
-33,000
-48% -$3.33M 0.25% 15
2023
Q4 		$6.86M Buy
69,000
+11,000
+19% +$925K 0.5% 16
2023
Q3 		$5.99M Buy
58,000
+22,500
+63% +$2.51M 0.55% 15
2023
Q2 		$4.31M Sell
35,500
-2,000
-5% -$267K 0.48% 14
2023
Q1 		$5.76M Buy
37,500
+1,500
+4% +$247K 0.89% 12
2022
Q4 		$6.47M Buy
36,000
+7,250
+25% +$1.19M 1.34% 8
2022
Q3 		$3.4M Sell
28,750
-16,750
-37% -$2.54M 0.73% 11
2022
Q2 		$6.5M Buy
45,500
+14,500
+47% +$2.07M 0.92% 13
2022
Q1 		$5.34M Buy
+31,000
New +$5.22M 0.44% 19

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lansdowne Partners (UK)'s MRNA Position: Q1 2025 in Review

Lansdowne Partners (UK) sold out of Moderna (MRNA) in Q1 2025, closing a stake of 35,000 shares — an estimated $1.46M sold.

Lansdowne Partners (UK) first reported a position in MRNA in Q1 2022 and held it in 11 quarters. The position peaked at $6.86M in Q4 2023. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • Lansdowne Partners (UK) reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • Lansdowne Partners (UK) sold 35,000 Moderna shares in Q1 2025, an estimated $1.46M.
  • Lansdowne Partners (UK) first reported a position in Moderna in Q1 2022 and held it in 11 quarters.
  • Lansdowne Partners (UK)'s Moderna position peaked at $6.86M in Q4 2023.
  • 693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Lansdowne Partners (UK)'s 13F filing for Q1 2025, filed 14 May 2025.